Literature DB >> 19333604

[Diagnostics and therapy of AA amyloidosis].

N Blank1, H M Lorenz.   

Abstract

AA amyloidosis can be the consequence of any chronic inflammatory disorder. It is most commonly associated with chronic inflammatory rheumatic, pulmonary or gastrointestinal diseases, familial Mediterranean fever or other rare periodic syndromes. AA amyloidosis often affects the kidneys, gastrointestinal tract and the heart. Effective therapy of the underlying disease can normalize the inflammatory reaction and can slow or inhibit the deterioration of organ function if the diagnosis is made at an early stage of the disease. In rheumatoid diseases and in some periodic syndromes the use of antibodies against TNFalpha or IL-1 beta might be helpful. Patients with familial Mediterranean fever should regularly take colchicine to prevent attacks and to reduce the risk for development or progression of AA amyloidosis. Eprodisate is currently being investigated for AA amyloidosis and renal involvement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333604     DOI: 10.1007/s00292-009-1140-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  29 in total

1.  Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

Authors:  M F McDermott; I Aksentijevich; J Galon; E M McDermott; B W Ogunkolade; M Centola; E Mansfield; M Gadina; L Karenko; T Pettersson; J McCarthy; D M Frucht; M Aringer; Y Torosyan; A M Teppo; M Wilson; H M Karaarslan; Y Wan; I Todd; G Wood; R Schlimgen; T R Kumarajeewa; S M Cooper; J P Vella; C I Amos; J Mulley; K A Quane; M G Molloy; A Ranki; R J Powell; G A Hitman; J J O'Shea; D L Kastner
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

2.  [Interdisciplinary guidelines for diagnosis and therapy of extracerebral amyloidosis: issued by the German Society of Amyloid Diseases e. V. (www.amyloid.de)].

Authors:  Christoph Röcken; Jutta Ernst; Ernst Hund; Hartmut Michels; Jolanta Perz; Wolfgang Saeger; Orhan Sezer; Simone Spuler; Friedrich Willig; Hartmut H-J Schmidt
Journal:  Med Klin (Munich)       Date:  2006-10-15

3.  "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis.

Authors:  T Kallinich; D Haffner; B Rudolph; R Schindler; S Canaan-Kühl; R Keitzer; G R Burmester; A Roesen-Wolff; J Roesler
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

4.  A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome.

Authors:  N M Lindor; T M Arsenault; H Solomon; C E Seidman; M T McEvoy
Journal:  Mayo Clin Proc       Date:  1997-07       Impact factor: 7.616

5.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

6.  Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis.

Authors:  Carlos D Rosé; Trudy M Doyle; Gail McIlvain-Simpson; Jessica E Coffman; James T Rosenbaum; Michael P Davey; Tammy M Martin
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

7.  Familial Hibernian fever.

Authors:  L M Williamson; D Hull; R Mehta; W G Reeves; B H Robinson; P J Toghill
Journal:  Q J Med       Date:  1982

8.  NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.

Authors:  Juan I Aróstegui; Cristina Arnal; Rosa Merino; Consuelo Modesto; María Antonia Carballo; Purificación Moreno; Julia García-Consuegra; Antonio Naranjo; Eduardo Ramos; Pilar de Paz; Josefa Rius; Susana Plaza; Jordi Yagüe
Journal:  Arthritis Rheum       Date:  2007-11

9.  Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis.

Authors:  Bouke P C Hazenberg; Johan Bijzet; Pieter C Limburg; Martha Skinner; Philip N Hawkins; Irena Butrimiene; Avi Livneh; Olga Lesnyak; Evgeney L Nasonov; Anna Filipowicz-Sosnowska; Ahmet Gül; Giampaolo Merlini; Piotr Wiland; Huri Ozdogan; Peter D Gorevic; Hédi Ben Maïz; Merrill D Benson; Haner Direskeneli; Kalevi Kaarela; Denis Garceau; Wendy Hauck; Martin H Van Rijswijk
Journal:  Amyloid       Date:  2007-06       Impact factor: 7.141

10.  Eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Laura M Dember; Philip N Hawkins; Bouke P C Hazenberg; Peter D Gorevic; Giampaolo Merlini; Irena Butrimiene; Avi Livneh; Olga Lesnyak; Xavier Puéchal; Helen J Lachmann; Laura Obici; Robert Balshaw; Denis Garceau; Wendy Hauck; Martha Skinner
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.